Healthcare, Pharma & Life Sciences

Rome – – November 03, 2026 --

The START Center for Cancer Research will open its first Italian early-phase oncology trial site inside Rome's IRCCS Istituto Nazionale Tumori Regina Elena, under a strategic partnership with the public hospital organization Istituti Fisioterapici Ospitalieri (IFO). The site will be fully integrated into START's network and will have access to its global trial portfolio from day one.

Italy's 390,000 annual cancer diagnoses meet a thinner trial footprint

Italy records approximately 390,000 new cancer diagnoses a year, according to the 2025 edition of the national report "I numeri del cancro in Italia," produced by AIOM and partner organizations. Despite that burden, Italy runs fewer clinical trials relative to its population than several major Western European markets, the companies said. They describe this gap as an opening for sponsors to reach patients through established research institutions.

Irvine, California – November 03, 2026 -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present nine abstracts at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, Nov. 5-8 in San Diego, including new data from two Phase 4 studies on aesthetic treatment in patients taking GLP-1-related medications for weight management.

Two Phase 4 studies track satisfaction and psychosocial outcomes after medical weight loss

Both studies will be shown as video oral abstracts and examine facial appearance, skin quality, patient satisfaction and psychosocial outcomes. One evaluates multimodal aesthetic treatment in a medical weight loss cohort (HARMONY IN DIVERSITY). The other assesses hyaluronic acid injectables in the same patient group.

SAN FRANCISCO – November 03, 2026 -- Thryv Therapeutics Inc. has raised a $30 million Series B financing led by InClin, Inc., a global contract research organization, to move its SGK1 inhibitor THRV-1268 into a Phase 2a heart failure study that opens for enrollment in early 2027.

The round follows completion of enrollment in the first efficacy cohort of the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome. It also follows a favorable review of available Wave II data by the study's Independent Data Monitoring Committee (IDMC).

InClin brings clinical operations alongside capital

InClin, which operates in San Mateo, California and Sydney, Australia, joins as a strategic investor. In recent months Thryv has worked with the CRO to establish clinical operations in Australia, enabling initial patient enrollment in ASPIRE-HF early next year.

NAPA, Calif. – November 03, 2026 -- Clinical judgment errors are the most common driver of radiology malpractice claims, according to a new analysis from The Doctors Company, the largest physician-owned medical malpractice insurer in the U.S.

November review draws on real claims data from a 2026 monthly specialty series

The insurer released "Radiology Claims: November Malpractice Risk Review." It is the latest edition in a monthly series that examines malpractice risk trends in a different medical specialty throughout 2026.

The review contains three analyses. The first covers contributing factors to patient harm. The second examines negligence allegations in radiology. The third is a case summary on missed diagnosis and communication failures.

Cambridge, Mass. – November 03, 2026 -- Zifo has launched an AI-assisted service accelerator that it estimates could cut computer system validation (CSV) documentation effort by up to 60 to 70 percent for regulated scientific organizations.

The service accelerator also covers instrument and equipment qualification. It uses AI-assisted document analysis and generation to produce requirements, risk assessments, test scenarios, test scripts, traceability matrices, and installation, operational, and performance qualification (IQ, OQ, PQ) documents. Validation experts review and approve all generated content and stay responsible for risk evaluation and final sign-off.

Zifo estimates gains of up to 75% across five validation metrics

The company's documented estimates, which it describes as potential improvements rather than guarantees, are:

Addison, Texas – November 03, 2026 -- FX Shoulder Solutions has secured certification under the European Union Medical Device Regulation (EU MDR 2017/745) for its Humelock Reversed Shoulder System, the first step in a plan to harmonize its product portfolio across international markets.

The company says the certification supports continued availability of the device in EU markets. Humelock Reversed is the legacy device to the FX V135 Humelock.

PMCF data show a 2.17% overall revision rate at three years

The company cites post-market clinical follow-up (PMCF) data from a cohort of 138 patients with at least three years of follow-up:

Berlin – November 03, 2026 -- Net costs for outpatient drug care in Germany's statutory health insurance reached a record €62.6 billion, according to an analysis by the AOK's Scientific Institute (WIdO) on the 2027 pharmaceutical market. Dr. Carola Reimann, chair of the AOK Federal Association, warned that a planned location clause could erase the savings the current cost-containment package delivers.

WIdO projects 2027 drug cost growth of 2.2% to 2.8%

The institute attributes the moderate outlook to the higher manufacturer rebate for 2027. It expects drug costs to rise by 2.2% to a maximum of 2.8%. WIdO experts caution that the relief is short-lived and call for structural reform, above all of the AMNOG procedure, which governs the pricing of new drugs.

Dijon – November 03, 2026 -- PROTEOR is introducing two lower-limb prosthetic feet worldwide: EXONEO CORE, built specifically for K2 ambulators, and HOPPER OUTSIDER, a foot designed to cover both everyday walking and dynamic activity.

EXONEO CORE targets the stability-versus-comfort trade-off for K2 users

EXONEO CORE is a biomimetic foot developed for community ambulators classified as K2. PROTEOR says a foot built for comfort can feel less stable, while a stable design can feel rigid. The company describes EXONEO CORE as purpose-built for K2 mobility rather than an adapted higher-activity foot.

Plantar springs absorb vertical loads and adapt to uneven terrain, and the foot keeps ground contact through toe-off. Natural toe extension of up to 20 degrees supports stability in the final phase of each step. The low-profile construction adds fitting versatility for clinicians.

Bronx, N.Y. – – November 03, 2026 -- The National Cancer Institute (NCI) has awarded a five-year, $10 million grant to a multi-institutional team led by Julio A. Aguirre-Ghiso, Ph.D., of Montefiore Einstein Comprehensive Cancer Center (MECCC). The money will fund research into the biological processes behind breast cancer relapse and into ways to predict and prevent recurrence.

The NCI estimates that up to 685,000 people die from breast cancer worldwide each year. Nearly all fatal cases involve disease that returns in other organs years or decades after surgery, chemotherapy or radiation.

Brookfield, Conn. – November 03, 2026 -- Medicare's CJR-X model will place 2,217 hospitals under mandatory two-sided financial risk on January 1, 2028. CMS's final rule projects those hospitals will repay $1.855 billion over five years while receiving $1.463 billion.

The model makes hospitals responsible for the full cost of hip, knee and ankle replacements through 90 days after discharge. Hospitals that beat a regional target price earn a bonus, while those that miss it pay Medicare back.

CMS projects a net $392 million transfer from hospitals to Medicare

The repayment gap leaves a net $392 million flowing to Medicare. More than half of the projected $736 million in savings comes from pricing alone.

Predecessor CJR left 60% of participating hospitals owing money in 2023

The earlier CJR program shows the direction of travel: